Vancouver, Canada

Artem Tcherkassov

USPTO Granted Patents = 7 

 

Average Co-Inventor Count = 4.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2009-2024

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Artem Tcherkassov

Introduction

Artem Tcherkassov is a prominent inventor based in Vancouver, Canada. He has made significant contributions to the field of cancer therapeutics, holding a total of 7 patents. His work focuses on developing innovative compounds that target specific cancer pathways, providing new avenues for treatment.

Latest Patents

Among his latest patents is the "Myc-Max inhibitor compound therapeutics for cancer treatment." This invention presents Myc-Max inhibitory compounds designed to treat various types of cancer, including prostate cancer, breast cancer, colon cancer, and more. Another notable patent is for "Binding Function 3 (BF3) site compounds as therapeutics and methods for their use," which outlines the use of specific compounds for treating prostate cancer and other indications.

Career Highlights

Artem Tcherkassov has worked at esteemed institutions such as the University of British Columbia and Simon Fraser University. His research has significantly advanced the understanding of cancer treatment methodologies, making him a key figure in the field.

Collaborations

Throughout his career, Tcherkassov has collaborated with notable colleagues, including Paul Rennie and Neil E. Reiner. These partnerships have fostered a collaborative environment that enhances research and innovation in cancer therapeutics.

Conclusion

Artem Tcherkassov's contributions to cancer treatment through his innovative patents and collaborations highlight his importance in the field of medical research. His work continues to pave the way for new therapeutic options for patients battling cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…